HEMOKINETIX
In development
Investigational medical device

A closed-loop platform for hemodynamic conditioning.

Hemokinetix integrates postural transition, lower-limb vascular compression, and respiratory pacing under ECG-derived biofeedback. The device is in development.

Stage Pre-market
IP US patent pending
Regulatory Pre-submission

Three synchronized inputs. One closed loop.

The device integrates three physiological stimuli in real-time coordination, with continuous ECG-derived feedback that closes the loop. Each input is mechanistically distinct; together they target the integrated autonomic and hemodynamic response.

01
Postural
Controlled postural transition via cantilever-based foot platform mechanism, producing vascular compression through joint angle changes.
02
Vascular
Lower-limb venous return modulation, integrated with the postural mechanism, to engage the baroreflex and respiratory sinus arrhythmia.
03
Respiratory
Respiratory pacing synchronized to real-time ECG feedback, closing the loop on cardiac and autonomic state.

Current development state.

Hemokinetix is in pre-market development. The information below reflects current state and is subject to change.

Stage
ActivePre-market development
Patent
US utility application pending
Trademark
HEMOKINETIX, Class 10, in clearance
FDA pathway
Under evaluation; pre-submission planning
Indication
Under evaluation
Clinical study
Protocol development

Twenty-five years at the intersection of autonomic physiology, respiratory mechanics, and biofeedback.

Noah McKenna is the founder and inventor of Hemokinetix. The device emerged from 25 years of clinical and research work at the intersection of autonomic physiology, respiratory mechanics, and heart rate variability biofeedback.

Noah holds an M.Sc. and is certified as a yoga therapist (C-IAYT) and experienced registered yoga teacher (E-RYT 500), with a research focus on resonant frequency breathing and vagal tone restoration. Prior to founding Hemokinetix, he developed clinical training programs in HRV biofeedback for licensed practitioners.

He leads Hemokinetix from concept through regulatory submission, with deep involvement in patent strategy, device design, and clinical protocol development.

Noah McKenna
Founder & CEO

Selective inbound. Considered response.

Hemokinetix is currently engaging selectively with medical device investors and regulatory advisors. We respond to qualified inquiries within five business days.

Investor inquiries
investors@hemokinetix.com

For seed and Series A medical device investors. Brief overview returned by reply; technical materials under mutual NDA.

Advisor inquiries
advisors@hemokinetix.com

For FDA-experienced regulatory, clinical, and quality advisors. Please include relevant clearance experience.